Guidelines for the management of postmenopausal osteoporosis for GPs

Aust Fam Physician. 2004 Nov;33(11):910-9.

Abstract

Background: Since the last series of guidelines on the management of osteoporosis from Osteoporosis Australia was published in Australian Family Physician (October 2002), there have been further advances in our understanding of the treatment involved in both the prevention of bone loss and the management of established osteoporosis.

Objective: This article provides updated guidelines for the management of postmenopausal osteoporosis to assist general practitioners identify those women at risk, and reviews current treatment strategies.

Discussion: Osteoporosis and its associated problems are major health concerns in Australia, especially with an aging population. While important principles of management are still considered to be maximising peak bone mass and preventing postmenopausal bone loss, new clinical trial data about drugs such as the bisphosphonates, raloxifene and oestrogen have recently become available and the relative role of various agents is gradually becoming clearer. The use of long term hormone therapy has mixed risks and benefits that requires individual patient counselling.

Publication types

  • Guideline
  • Practice Guideline

MeSH terms

  • Absorptiometry, Photon
  • Aged
  • Antihypertensive Agents / therapeutic use
  • Benzothiadiazines
  • Biomarkers / blood
  • Bone Diseases, Metabolic / complications
  • Bone Diseases, Metabolic / diagnosis
  • Bone Diseases, Metabolic / therapy
  • Calcium / therapeutic use
  • Diphosphonates / therapeutic use
  • Diuretics
  • Drug Therapy, Combination
  • Estrogen Replacement Therapy / methods
  • Family Practice / methods*
  • Family Practice / standards*
  • Female
  • Fractures, Bone / etiology
  • Fractures, Bone / prevention & control
  • Humans
  • Middle Aged
  • Organometallic Compounds / therapeutic use
  • Osteoporosis, Postmenopausal / blood
  • Osteoporosis, Postmenopausal / complications
  • Osteoporosis, Postmenopausal / diagnosis*
  • Osteoporosis, Postmenopausal / therapy*
  • Parathyroid Hormone / therapeutic use
  • Risk Factors
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Sodium Chloride Symporter Inhibitors / therapeutic use
  • Thiophenes / therapeutic use
  • Vitamin D / therapeutic use

Substances

  • Antihypertensive Agents
  • Benzothiadiazines
  • Biomarkers
  • Diphosphonates
  • Diuretics
  • Organometallic Compounds
  • Parathyroid Hormone
  • Selective Estrogen Receptor Modulators
  • Sodium Chloride Symporter Inhibitors
  • Thiophenes
  • strontium ranelate
  • Vitamin D
  • Calcium